Page last updated: 2024-12-08

fludrocortisone acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fludrocortisone acetate : An acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid actions are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID225609
CHEMBL ID1201010
CHEBI ID5102
SCHEMBL ID4737

Synonyms (107)

Synonym
AC-18903
[2-[(8s,9r,10s,11s,13s,14s,17r)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
(11beta)-9-fluoro-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl acetate
9alpha-fluoro-11beta,17alpha,21-trihydroxy-pregn-4-en-3,20-dione 21-acetate
LMST02030122
fluorocortisol acetate
fluohydrocortisone acetate
alflorone acetate
9.alpha.-fluorohydrocortisone acetate
f-cortef acetate
fludrocortisone 21-acetate
nsc15186
u 4845
9.alpha.-fluorohydrocortisone-21-acetate
pregn-4-ene-3, 9-fluoro-11.beta.,17,21-trihydroxy-, 21-acetate
florinef acetate
wln: l e5 b666 ov mutj a1 bf cq e1 fv1ov1 fq
mls002638417 ,
9.alpha.-fluorocortisol acetate
cortineff
nsc-15186
scherofluron
pregn-4-ene-3, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11.beta.)-
cortef-f
9.alpha.-fluorohydrocortisone 21-acetate
fluorocortisone acetate
PRESTWICK2_000281
9alpha-fluorohydrocortisone 21-acetate
9-alpha-fluorohydrocortisone-21-acetate
fludrocortisone acetate [jan]
9-fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate
pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-, 21-acetate
nsc 15186
9-alpha-fluorohydrocortisone acetate
pregn-4-ene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11beta)-
brn 2067486
9alpha-fluorohydrocortisone acetate
corticosterone, 9-fluoro-17-hydroxy-, 21-acetate
einecs 208-180-4
pregn-4-ene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-, 21-acetate
cortisol, 9-fluoro-, 21-acetate
9-fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate
C08186
514-36-3
fludrocortisone acetate
fludrocortisone acetate, >=98%
D00986
fludrocortisone acetate (jp17/usp)
florinef acetate (tn)
PRESTWICK0_000281
PRESTWICK1_000281
SPBIO_002401
fludrocortisoni acetas
CHEMBL1201010
chebi:5102 ,
fluorhydrocortisone acetate
[2-[(9r,10s,11s,13s,17r)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
HMS1568J04
9 alpha-fluorocortisol acetate
fludrocortisone acetate [usp:jan]
v47if0pvh4 ,
unii-v47if0pvh4
S3659
AKOS015963145
fludrocortisone 21-acetate [mi]
fludrocortisone acetate [usp monograph]
fludrocortisone acetate [orange book]
fludrocortisoni acetas [who-ip latin]
fludrocortisone acetate [who-dd]
fludrocortisone acetate [vandf]
fludrocortisone acetate [usp-rs]
fludrocortisone acetate [who-ip]
pregn-4-ene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11.beta.)-
fludrocortisone acetate [ep monograph]
fludrocortisone acetate [mart.]
SCHEMBL4737
CS-4833
fludrocortisonacetat
SYWHXTATXSMDSB-GSLJADNHSA-N
2-((8s,9r,10s,11s,13s,14s,17r)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
9-fluoro-11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl acetate
Q-201121
HY-B1203A
DTXSID2023062 ,
fludrocortisone (acetate)
9a-fludrocortisone acetate
9a-fluorcortisol acetate
9a-fluorocortisol acetate
fludrocortisone acetate, united states pharmacopeia (usp) reference standard
fludrocortisone acetate, european pharmacopoeia (ep) reference standard
9-fluoro-11|a, 17, 21-trihydroxypregn-4-ene-3, 20-dione 21-acetate
DS-3879
Q27106657
fludrocortisone-acetate
CCG-268914
pregn-4-ene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-,(11b)-
514-36-3 (acetate)
fludrocortisoneacetate
CS-0694918
HY-B1203AR
fludrocortisone acetate (standard)
dtxcid903062
fludrocortisone acetate (ep monograph)
fludrocortisone acetate (mart.)
fludrocortisone acetate (usp monograph)
fludrocortisone acetate (usp:jan)
fludrocortisone acetate (usp-rs)

Research Excerpts

Overview

Fludrocortisone acetate (Florinef) is a synthetic steroid with a potent mineralocorticoid action. Used for treatment of Addison's disease and congenital adrenal hyperplasia.

ExcerptReferenceRelevance
"Fludrocortisone acetate is a drug used to treat adrenal insufficiencies which can be prescribed to hospitalized or ambulatory pediatric patients at dosages not commercially available. "( Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates).
Bertault-Peres, P; Bouguergour, C; Brandin, T; Curti, C; Jean, C; Lamy, E; Panuccio, C; Primas, N; Rathelot, P; Vanelle, P; Wasilewski, M,
)
1.89
"Fludrocortisone acetate (Florinef) is a synthetic steroid with a potent mineralocorticoid action, and used for treatment of Addison's disease and salt losing form of congenital adrenal hyperplasia. "( [Synthetic mineralocorticoid].
Miyamori, I, 2008
)
1.79

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Adverse events (AEs) were reported from the first dose of FCA until the end-of-study visit."( Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy.
Chang, A; Hong, T; Maddess, T; Penfold, P; Provis, J, 2022
)
0.95
"IVT FCA is clinically safe and well tolerated and did not increase IOP."( Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy.
Chang, A; Hong, T; Maddess, T; Penfold, P; Provis, J, 2022
)
0.95

Dosage Studied

ExcerptRelevanceReference
" Thus, the development of sustained-release forms, as microparticle suspensions, is interesting in order to improve patient compliance by reducing dosing frequencies and side effects."( Poly(epsilon-caprolactone) and Eudragit microparticles containing fludrocortisone acetate.
Astier, A; Ducki, C; Gibaud, S; Jabir Al Awwadi, N, 2004
)
0.56
" Aims of this study were to assess the influence of sex and body weight on GC dosing and to describe the choice of GC in AI of different etiologies."( What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study.
Borretta, G; Cannavò, S; Dughera, F; Ferrau', F; Latina, A; Parisi, A; Pellegrino, M; Pia, A; Puglisi, S; Ragonese, M; Reimondo, G; Rossini, A; Tabaro, I; Terzolo, M, 2021
)
0.62
" First, a stability-indicating fludrocortisone acetate dosing method was validated."( Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates).
Bertault-Peres, P; Bouguergour, C; Brandin, T; Curti, C; Jean, C; Lamy, E; Panuccio, C; Primas, N; Rathelot, P; Vanelle, P; Wasilewski, M,
)
0.74
" Two subsequent participants were then dosed with the same dose."( Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy.
Chang, A; Hong, T; Maddess, T; Penfold, P; Provis, J, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (8)

ClassDescription
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
mineralocorticoidMineralocorticoids are a class of steroid hormones that regulate water and electrolyte metabolism.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
fluorinated steroidA steroid which is substituted with one or more fluorine atoms in any position.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)0.02000.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki0.00930.00010.38637.0010AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.02000.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.00930.00070.76537.0010AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)0.02000.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki0.00930.00070.78467.0010AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.02000.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.00930.00070.78467.0010AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.02000.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.00930.00070.78467.0010AID625263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID90104Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID91224Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID188016Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (33.33)18.7374
1990's5 (7.25)18.2507
2000's15 (21.74)29.6817
2010's23 (33.33)24.3611
2020's3 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.80 (24.57)
Research Supply Index4.41 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index117.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (8.00%)5.53%
Reviews9 (12.00%)6.00%
Case Studies15 (20.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]